TAXOL |
1. Introduction |
The story of paclitaxel (now commonly known under the registered tradename Taxol ®) originated in ancient times. Julius Caesar mentioned in his "Gallic Wars" that Catulvolcus committed suicide by consuming extracts from the yew tree1. There are also numerous ![]() In 1971 Wall, Wani and coworkers at the Research Triangle Institute, North Carolina reported the molecular structure of taxol (1) on the basis of X-ray crystallographic data4.
Taxol's journey to the clinic was slow because of difficulties with aqueous solubility and lack of knowledge of the mechanism by which it attacked cancer cells. In 1979 however, Dr. S.B. Horwitz and her collaborators published a paper disclosing their findings on the interaction of taxol with microtubules5. This led the way for development of taxol as a potential drug candidate. Phase I clinical trials began in 1983 with taxol in short supply. The problem of procuring adequate supplies of taxol became even more acute when environmentalists, concerned with the endangering of various species that live in the ancient yew tree forests of North America raised objections to their destruction. This led to research efforts on the synthesis of taxol intensifying and a number of groups began their approaches. |